X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (68) 68
hygiene (68) 68
medical or veterinary science (68) 68
preparations for medical, dental, or toilet purposes (68) 68
performing operations (49) 49
transporting (49) 49
specific therapeutic activity of chemical compounds ormedicinal preparations (40) 40
general tagging of cross-sectional technologies spanning over several sections of the ipc (37) 37
general tagging of new technological developments (37) 37
technical subjects covered by former uspc (37) 37
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (37) 37
technical subjects covered by former uspc cross-reference artcollections [xracs] and digests (37) 37
chemistry (26) 26
heterocyclic compounds (26) 26
manufacture or treatment of nanostructures (26) 26
measurement or analysis of nanostructures (26) 26
metallurgy (26) 26
nanotechnology (26) 26
organic chemistry (26) 26
specific uses or applications of nanostructures (26) 26
chemical or physical processes, e.g. catalysis or colloidchemistry (23) 23
physical or chemical processes or apparatus in general (23) 23
technical subjects covered by former us classification (23) 23
their relevant apparatus (23) 23
animals (12) 12
humans (9) 9
rats (8) 8
male (7) 7
index medicus (5) 5
aged (4) 4
biochemistry & molecular biology (4) 4
pharmacology & pharmacy (4) 4
adult (3) 3
biophysics (3) 3
cardiac & cardiovascular systems (3) 3
drug carriers (3) 3
female (3) 3
mice (3) 3
middle aged (3) 3
rna, messenger - metabolism (3) 3
thyroxine-binding proteins - metabolism (3) 3
tissue distribution (3) 3
abridged index medicus (2) 2
acute coronary syndromes (2) 2
administration & dosage (2) 2
adverse effects (2) 2
aging (2) 2
angiogenesis (2) 2
anticoagulants (2) 2
aspirin (2) 2
aspirin - administration & dosage (2) 2
aspirin - adverse effects (2) 2
aspirin - therapeutic use (2) 2
autoradiography (2) 2
cardiovascular disease (2) 2
cardiovascular diseases (2) 2
cardiovascular diseases - mortality (2) 2
cardiovascular diseases - prevention & control (2) 2
cells, cultured (2) 2
chemically induced (2) 2
clinical medicine (2) 2
clinical trials (2) 2
combination (2) 2
coronary vessels (2) 2
cyanoacrylates (2) 2
disease control (2) 2
disease prevention (2) 2
dose-response relationship (2) 2
dose-response relationship, drug (2) 2
double-blind method (2) 2
doxorubicin - administration & dosage (2) 2
doxorubicin - pharmacokinetics (2) 2
drug (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
drug therapy, combination (2) 2
epidemiology (2) 2
factor xa inhibitors (2) 2
factor xa inhibitors - administration & dosage (2) 2
factor xa inhibitors - adverse effects (2) 2
factor xa inhibitors - therapeutic use (2) 2
health risk assessment (2) 2
heart attacks (2) 2
hemorrhage (2) 2
hemorrhage - chemically induced (2) 2
immunoelectrophoresis, two-dimensional (2) 2
inflammation (2) 2
klinisk medicin (2) 2
liver - metabolism (2) 2
medicine, general & internal (2) 2
morbidity (2) 2
mortality (2) 2
muscle, smooth, vascular - pathology (2) 2
myocardial infarction (2) 2
myocardial infarction - epidemiology (2) 2
myocardial infarction - prevention & control (2) 2
myocytes, smooth muscle - pathology (2) 2
obesity (2) 2
oncology (2) 2
peripheral vascular disease (2) 2
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (64) 64
French (17) 17
German (16) 16
Danish (4) 4
Spanish (4) 4
Finnish (3) 3
Norwegian (3) 3
Swedish (3) 3
Polish (2) 2
Portuguese (2) 2
Chinese (1) 1
Indonesian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Diaz, Rafael and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Maggioni, Aldo P and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Bhatt, Deepak L and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Avezum, Alvaro A and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
by Connolly, Stuart J and Eikelboom, John W and Bosch, Jackie and Dagenais, Gilles and Dyal, Leanne and Lanas, Fernando and Metsarinne, Kaj and O'Donnell, Martin and Dans, Anthony L and Ha, Jong-Won and Parkhomenko, Alexandr N and Avezum, Alvaro A and Lonn, Eva and Lisheng, Liu and Torp-Pedersen, Christian and Widimsky, Petr and Maggioni, Aldo P and Felix, Camilo and Keltai, Katalin and Hori, Masatsugu and Yusoff, Khalid and Guzik, Tomasz J and Bhatt, Deepak L and Branch, Kelley R H and Cook Bruns, Nancy and Berkowitz, Scott D and Anand, Sonia S and Varigos, John D and Fox, Keith A A and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and RECH, RAFAEL and ... and COMPASS Investigators and COMPASS investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | ORAL RIVAROXABAN | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Drug | drug therapy | chemically induced | prevention & control | Coronary Artery Disease | Clinical Medicine | Myocardial Infarction | Platelet Aggregation Inhibitors | adverse effects | mortality | Dose-Response Relationship | therapeutic use
Journal Article
Adipocyte, ISSN 2162-3945, 01/2014, Volume 3, Issue 1, pp. 46 - 49
The fibroblast growth factor (FGF)-FGF receptor (FGFR) system plays a role in angiogenesis and maintenance of vascular integrity, but its potential role in... 
adipose tissue | fibroblast growth factor | mouse model | angiogenesis | obesity | Brief Report
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1990, Volume 26, Issue 1, pp. 13 - 18
The body distribution of i.v. doxorubicin depends mainly on the physicochemical characteristics of the molecule. However, entrapment of that cytostatic drug... 
ONCOLOGY | PHARMACOLOGY & PHARMACY | Injections, Intravenous | Feces - analysis | Chromatography, High Pressure Liquid | Doxorubicin - pharmacokinetics | Drug Carriers | Particle Size | Tissue Distribution | Autoradiography | Cyanoacrylates | Animals | Mice | Doxorubicin - urine | Doxorubicin - administration & dosage
Journal Article